| Name | Title | Contact Details |
|---|
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
Founded by industry pioneers who championed the world`s leading hemp CBD genetics, formulations and spearheaded groundbreaking US hemp legislation, GenCanna ™ is focused on scaling our premium hemp genetics production for food products with easy availability locally, nationally and globally.
PT Development (PTD) is a Louisville-based operational management firm that specializes in providing operational efficiencies such as accounting, customer service, marketing, compliance, and human resource services to privately held physical therapy practices. Founded by Dr. Larry Benz in 1994, PTD’s primary goal is to help our clients achieve clinical excellence through aligning business strategies, streamlining processes, and building equity through quality customer service.